Advertisement
Advertisement
U.S. markets close in 4 hours 41 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.0990-0.0610 (-1.93%)
As of 11:17AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close3.1600
Open3.1500
Bid3.1000 x 900
Ask3.1100 x 800
Day's Range3.0900 - 3.2200
52 Week Range1.7100 - 14.4200
Volume73,332
Avg. Volume743,723
Market Cap258.352M
Beta (5Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)-1.5440
Earnings DateNov 03, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GRTS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gritstone bio, Inc.
    XNCR: Lowering target price to $30.00XENCOR INC has an Investment Rating of HOLD; a target price of $30.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted nine employees nonqualified stock options to purchase an aggregate of 72,300 shares of its common stock with an exercise price of $3.03, which is equal to the closing price of Gritstone’s common stock on November 11, 2022, the date of the grant. These st

  • GlobeNewswire

    Gritstone to Participate in Upcoming Investor Conferences

    EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Gritstone management will participate in the following upcoming investor conferences. 5th Annual Evercore ISI HealthCONx ConferenceFireside Chat Date and Time: Tuesday, November 29, 2022 at 10:30am ESTPresenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive OfficerLocati

  • GlobeNewswire

    Gritstone Announces Updated Overall Survival Results from GRANITE Phase 1/2 Study and Poster at SITC 2022

    -- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response will now exceed 22 months – median not yet reached -- -- Patients who achieve a molecular response include those with liver metastasis and are not enriched for baseline PD-L1 expression, high tumor mutation burden or IFNg-related genes -- EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS

Advertisement
Advertisement